Research Use Only. The information presented here is for scientific and educational purposes. These compounds are not intended for human consumption, self-administration, or therapeutic use.
Introduction
Two research peptides frequently appear in the same lipolysis literature while sharing almost nothing structurally. AOD-9604 is a sixteen-residue fragment carved from the tail of human growth hormone and studied directly at the adipocyte. Tesamorelin is a forty-four-residue growth-hormone-releasing hormone analog studied at the pituitary, several steps upstream of any fat cell. Both are examined for endpoints related to lipid mobilization, which is why they are compared, but they enter the system at opposite ends.
Understanding that difference determines what a given experiment can actually show. This article sets the two side by side on molecular identity, point of entry, and the signaling that follows, drawing only on in-vitro and animal-model work. AOD-9604 and Tesamorelin are laboratory materials supplied for research use only, not for human consumption.
Two Molecules, Two Points of Entry
Human growth hormone is a 191-amino-acid protein of roughly 22 kDa with several functionally distinct regions. One research tradition asks what happens when a specific region is isolated from the rest; the other asks what happens when the hormone’s own release is stimulated by the peptide that governs it. AOD-9604 belongs to the first tradition and Tesamorelin to the second.
The values below reflect commonly reported laboratory attributes and are provided for comparison only.
| Attribute | AOD-9604 | Tesamorelin |
|---|---|---|
| Class | Growth hormone C-terminal fragment analog | GHRH analog (growth hormone secretagogue) |
| Parent molecule | Human growth hormone, residues 176-191 | Growth-hormone-releasing hormone (1-44) |
| Sequence length | 16 amino acids | 44 amino acids |
| Approx. molecular weight | ~1815 Da | ~5136 Da |
| Structural modification | N-terminal tyrosine added to the fragment | trans-3-hexenoyl group on the N-terminal tyrosine |
| Studied point of entry | Adipose tissue, at or near the fat cell | Pituitary somatotroph, upstream of the fat cell |
| Receptor target studied | No single established receptor | GHRH receptor (class B GPCR) |
AOD-9604: A Fragment Studied at the Fat Cell
The premise behind aod 9604 research is separability: that the lipid-mobilizing region of growth hormone can be isolated from the regions responsible for its other activities. The compound corresponds to the hormone’s C-terminal segment, residues 176 to 191, with a tyrosine added at the N-terminus, giving sixteen residues stabilized by a single disulfide bond.
Lipolysis and Lipogenesis Endpoints
Preclinical work on the fragment has used rodent adipose tissue and isolated adipocyte preparations, with two complementary readouts: whether stored lipid is mobilized, and whether new lipid synthesis is reduced. Reports in these models describe activity on both, which is why the fragment is characterized as acting on lipid handling rather than on a single direction of flux. Because the sequence is short and lacks the receptor-binding regions of the intact hormone, no single established receptor has been assigned to it.
The Beta-3 Adrenergic Receptor Question
One recurring thread concerns the beta-3 adrenergic receptor, the adrenergic subtype most associated with lipolysis in rodent adipose tissue. Some rodent studies examined changes in beta-3 receptor expression following fragment exposure, and the receptor became a candidate mediator. Later work has questioned whether it is required for the observed activity, and the mechanism remains an open question in the literature rather than a settled pathway. The AOD-9604 literature is best read with that uncertainty intact.
Reported Separation from the Growth Axis
The feature that most distinguishes the fragment from intact growth hormone in animal studies is what it reportedly does not do. Published reports describe the fragment as not producing the increases in circulating IGF-1 or the changes in glucose handling associated with the whole hormone. Within a study design, this is what makes it useful: it allows lipid endpoints to be examined without the confound of a systemically activated growth axis.
Tesamorelin: A GHRH Analog Studied Upstream
Tesamorelin approaches the same endpoints from the top of the axis. It is a synthetic analog of the full 44-amino-acid growth-hormone-releasing hormone, modified by attaching a trans-3-hexenoyl group to the N-terminal tyrosine.
Why the Modification Exists
Native GHRH is rapidly cleaved between residues 2 and 3 by dipeptidyl peptidase-4, which limits its persistence in circulation. The hexenoyl group at the N-terminus is a stabilizing modification that reduces susceptibility to that cleavage, extending the window over which the analog can engage its receptor in animal pharmacokinetic studies.
The Signaling Chain
The analog binds the GHRH receptor, a class B G-protein-coupled receptor on pituitary somatotrophs, raising intracellular cyclic AMP and prompting release of stored growth hormone in a pulsatile pattern. Growth hormone then acts at two places relevant to this comparison: on hepatocytes, where it drives IGF-1 production, and on adipose tissue, where growth hormone signaling is studied in relation to hormone-sensitive lipase activity and lipoprotein lipase suppression. Any lipid endpoint observed with a GHRH analog is therefore several steps removed from the compound itself, and the intact feedback loop, in which IGF-1 and somatostatin restrain further release, remains in the circuit. Related secretagogues including Sermorelin and CJC-1295 act on the same receptor with different stabilization strategies.
Comparing the Two Approaches in Study Design
The practical distinction is how many biological steps sit between the compound and the measurement. A direct-acting fragment produces a short causal chain that is easy to attribute; an upstream secretagogue produces a longer chain in which the axis itself is part of the experiment. The comparison below reflects commonly reported laboratory attributes and is provided for comparison only.
| Design Consideration | AOD-9604 | Tesamorelin |
|---|---|---|
| Steps to the endpoint | Direct at adipose tissue | Pituitary, then growth hormone, then tissue |
| Growth axis engagement | Reported as minimal | Central to the mechanism |
| IGF-1 involvement | Not a reported feature | Expected downstream consequence |
| Feedback regulation | Not applicable | Somatostatin and IGF-1 feedback preserved |
| Common model systems | Isolated adipocytes, rodent adipose tissue | Whole-animal endocrine models, pituitary cell assays |
| Typical assay readouts | Glycerol and free fatty acid release, lipogenic markers | Growth hormone pulse profile, circulating IGF-1 |
Neither approach is the more informative one in the abstract. A question about adipocyte biology is poorly served by a compound whose effects arrive through three intermediates, while a question about axis regulation cannot be answered by a fragment that reportedly bypasses the axis. Investigators comparing metabolic research peptides often include compounds from other categories as well, such as the mitochondrial-derived peptide MOTS-c, precisely because grouping by studied endpoint rather than by mechanism obscures these distinctions.
Handling and Verification Notes
Both compounds ship as lyophilized powders and both are handled cold, but their size difference matters at the bench. As a worked example, reconstituting a 5 mg AOD-9604 vial with 2 mL of bacteriostatic water yields a 2.5 mg/mL stock; the same volume added to a 10 mg vial of a larger peptide gives 5 mg/mL, and the molar concentrations differ by roughly a factor of three at equal mass because of the weight gap between a 1.8 kDa fragment and a 5.1 kDa analog. Molar rather than mass equivalence is the meaningful basis for comparison. The bacteriostatic water guide covers the arithmetic in full.
Identity verification differs as well. A short fragment with one disulfide bond is straightforward to confirm by mass, while a 44-residue analog carrying an acyl modification requires the reported mass to include that group. Reading lot documentation with the COA guide and reviewing published certificates of analysis is the check that the material matches the compound described. AOD-9604 and Tesamorelin both appear in the research peptide catalog as laboratory materials only, two distinct entry points into the same set of questions.
Frequently Asked Questions
What is the difference between AOD-9604 and Tesamorelin?
AOD-9604 is a 16-residue fragment of human growth hormone studied for direct activity at adipose tissue. Tesamorelin is a 44-residue GHRH analog studied at the pituitary, where it stimulates growth hormone release. One acts at the end of the chain, the other at the beginning.
How does AOD-9604 work in lipolysis research?
In rodent adipose tissue and isolated adipocyte models it is examined for effects on both lipid mobilization and lipid synthesis. No single receptor has been established for it; the beta-3 adrenergic receptor has been examined as a candidate mediator, and whether it is required remains an open question in the literature.
Does AOD-9604 raise IGF-1 the way growth hormone does?
Published animal reports describe the fragment as not producing the IGF-1 increases or glucose changes associated with the intact hormone. That reported separation from the growth axis is a large part of why the fragment is studied on its own.
Why is Tesamorelin modified with a hexenoyl group?
Native GHRH is cleaved between residues 2 and 3 by dipeptidyl peptidase-4. Attaching a trans-3-hexenoyl group to the N-terminal tyrosine reduces susceptibility to that cleavage, extending the analog’s persistence in animal pharmacokinetic studies.
What are the molecular weights of aod 9604 and Tesamorelin?
AOD-9604 is commonly reported near 1815 Da across roughly 16 residues with a single disulfide bond. Tesamorelin is commonly reported near 5136 Da across 44 residues including its acyl modification. These values reflect commonly reported laboratory attributes and are provided for comparison only.
Are AOD-9604 and Tesamorelin intended for human use?
No. Both are supplied strictly as laboratory materials for research use only, not for human consumption or self-administration. The observations summarized here come from in-vitro assays and animal models.
References and Further Reading
- Lipolytic activity associated with the C-terminal region of human growth hormone. PubMed: growth hormone fragment 176-191 lipolytic
- Rodent studies of the growth hormone fragment and adipose tissue metabolism. PubMed: AOD-9604 adipose tissue rodent
- Beta-3 adrenergic receptor signaling in adipose tissue lipolysis. PubMed: beta-3 adrenergic receptor lipolysis adipocyte
- GHRH receptor pharmacology and pituitary growth hormone release. PubMed: GHRH receptor pituitary growth hormone release
- Structural stabilization of GHRH analogs against dipeptidyl peptidase-4 cleavage. PubMed: GHRH analog dipeptidyl peptidase 4 stability
- Growth hormone signaling in adipose tissue, including hormone-sensitive lipase and lipoprotein lipase. PubMed: growth hormone adipose tissue lipolysis lipase
- Tesamorelin studies of the growth hormone and IGF-1 axis. PubMed: tesamorelin growth hormone IGF-1
